Michael Yee
Stock Analyst at Jefferies
(3.13)
# 1,235
Out of 5,090 analysts
78
Total ratings
45.28%
Success rate
14.14%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALXO ALX Oncology Holdings | Upgrades: Buy | $2 → $3 | $1.42 | +111.27% | 5 | Mar 6, 2025 | |
| KOD Kodiak Sciences | Upgrades: Buy | $20 | $24.34 | -17.83% | 3 | Dec 9, 2024 | |
| BIIB Biogen | Downgrades: Hold | $250 → $180 | $181.30 | -0.72% | 5 | Dec 9, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $500 → $550 | $455.48 | +20.75% | 4 | Dec 9, 2024 | |
| AMGN Amgen | Maintains: Buy | $380 | $329.89 | +15.19% | 5 | Nov 12, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $40 → $45 | $19.96 | +125.45% | 2 | Nov 1, 2024 | |
| MRNA Moderna | Maintains: Hold | $65 → $55 | $27.70 | +98.56% | 8 | Oct 15, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $35 | $31.97 | +9.48% | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $40 | $30.84 | +29.70% | 1 | Sep 13, 2024 | |
| AXON Axon Enterprise | Initiates: Buy | $385 | $550.95 | -30.12% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1.4 → $10 | $8.55 | +16.96% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $6.40 | -53.13% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $30 | $27.09 | +10.74% | 2 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $16.54 | +20.92% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $20 | $45.02 | -55.58% | 3 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 → $75 | $9.99 | +650.75% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $8.72 | +244.04% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $38.78 | +67.61% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,875 → $1,125 | $8.42 | +13,261.05% | 2 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $3.73 | +704.29% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $11.07 | +171.00% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $35.01 | +242.76% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $70 → $75 | $17.64 | +325.17% | 2 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $89.47 | -66.47% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $22.98 | +235.07% | 2 | Nov 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $121.22 | - | 3 | Jan 26, 2018 |
ALX Oncology Holdings
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $1.42
Upside: +111.27%
Kodiak Sciences
Dec 9, 2024
Upgrades: Buy
Price Target: $20
Current: $24.34
Upside: -17.83%
Biogen
Dec 9, 2024
Downgrades: Hold
Price Target: $250 → $180
Current: $181.30
Upside: -0.72%
Vertex Pharmaceuticals
Dec 9, 2024
Upgrades: Buy
Price Target: $500 → $550
Current: $455.48
Upside: +20.75%
Amgen
Nov 12, 2024
Maintains: Buy
Price Target: $380
Current: $329.89
Upside: +15.19%
Denali Therapeutics
Nov 1, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $19.96
Upside: +125.45%
Moderna
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $27.70
Upside: +98.56%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $31.97
Upside: +9.48%
Oruka Therapeutics
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $30.84
Upside: +29.70%
Axon Enterprise
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $550.95
Upside: -30.12%
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $8.55
Upside: +16.96%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $6.40
Upside: -53.13%
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $27.09
Upside: +10.74%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $16.54
Upside: +20.92%
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $45.02
Upside: -55.58%
Jan 6, 2023
Upgrades: Buy
Price Target: $63 → $75
Current: $9.99
Upside: +650.75%
Nov 15, 2021
Initiates: Buy
Price Target: $30
Current: $8.72
Upside: +244.04%
Mar 2, 2021
Initiates: Buy
Price Target: $65
Current: $38.78
Upside: +67.61%
Mar 2, 2021
Downgrades: Hold
Price Target: $1,875 → $1,125
Current: $8.42
Upside: +13,261.05%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $3.73
Upside: +704.29%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $11.07
Upside: +171.00%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $35.01
Upside: +242.76%
Oct 12, 2020
Upgrades: Buy
Price Target: $70 → $75
Current: $17.64
Upside: +325.17%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $89.47
Upside: -66.47%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $22.98
Upside: +235.07%
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $121.22
Upside: -